We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 662

Acute impact decision on descriptive additions to pharmaceutical brand names
  • Latham & Watkins LLP
  • Germany
  • August 8 2013

The Higher Administrative Court of Northrhine-Westphalia (Oberverwaltungsgericht NRW OVG-NRW) has upheld a decision by the Administrative Court of

Risk-sharing and other new business models for pharmaceutical companies in Germany
  • Hogan Lovells
  • Germany
  • August 31 2008

The German Federal Law to Increase Competition among Statutory Health Insurance Funds from April 1, 2007 has ushered in major changes regarding the way pharmaceutical companies do business in Germany

The German Plavix case: loopholes in European data protection?
  • Jones Day
  • Germany
  • September 1 2008

Originators beware: the marketing authorization granted by the German authority for a generic formulation of Plavix, and the subsequent decision of the competent court in preliminary proceedings to allow the marketing of the drug, raises questions about the protection of data under the European regulatory framework

Los genéricos y las empresas que les suministran: nueva cuestión prejudicial
  • Abril Abogados
  • European Union, Germany
  • February 22 2014

El tribunal superior de justicia de Dusseldorf (Alemania) ha elevado cuestion prejudicial al Tribunal de Justicia sobre la relacion

Generic drug and API producers deal with the Bolar exemption
  • McDermott Will & Emery
  • Germany
  • February 26 2014

To allow generic drug companies to enter the market as seamlessly as possible after expiration of patent rights, the Bolar exemption allows certain

Standard distribution agreements for pharmaceutical products
  • SKW Schwarz Rechtsanwälte
  • Germany
  • July 22 2015

Manufacturers of pharmaceutical products not only sell products themselves, but also use external partners to get their products to market and to

Court rules on protection terms for further developments of reference medicinal products
  • SKW Schwarz Rechtsanwälte
  • European Union, Germany
  • August 12 2015

The further development of an original product with other therapeutic indications, active ingredient strengths or dosages that have their own

Government draft of e-health law
  • SKW Schwarz Rechtsanwälte
  • Germany
  • September 9 2015

The government has started to strengthen digital networking in the field of e-health. In future, a doctor will be able to retrieve important

International news: focus on compliance - winter 2014
  • McDermott Will & Emery
  • China, European Union, Germany, Global, USA
  • December 2 2014

As regulatory oversight of companiesfrom Sarbanes Oxley and the Dodd-Frank Act to the Foreign Corrupt Practices Act (FCPA) and the UK Bribery

Horizonte 2015
  • Norton Rose Fulbright LLP
  • European Union, Germany
  • February 11 2015

Seit Mitte 2013 können wir durch unsere Präsenz auch im US-amerikanischen Markt ein globales Profil anbieten, das den vielfältigen Anforderungen